Charles River Laboratories International (NYSE:CRL) Now Covered by Barclays

Barclays started coverage on shares of Charles River Laboratories International (NYSE:CRL) in a report released on Friday, Benzinga reports. The brokerage issued an equal weight rating and a $230.00 price target on the medical research company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating on the stock in a research note on Friday, May 10th. TD Cowen lowered their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a hold rating on the stock in a research note on Monday, May 13th. The Goldman Sachs Group assumed coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They issued a buy rating and a $290.00 price objective on the stock. Mizuho assumed coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They issued a neutral rating and a $235.00 price objective on the stock. Finally, StockNews.com cut shares of Charles River Laboratories International from a buy rating to a hold rating in a research note on Friday, June 14th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Hold and an average target price of $254.50.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $203.08 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The stock has a market capitalization of $10.46 billion, a P/E ratio of 23.89, a P/E/G ratio of 1.95 and a beta of 1.38. The company’s fifty day moving average is $219.57 and its two-hundred day moving average is $232.55. Charles River Laboratories International has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, sell-side analysts predict that Charles River Laboratories International will post 11 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. LPL Financial LLC raised its holdings in Charles River Laboratories International by 14.5% in the third quarter. LPL Financial LLC now owns 38,349 shares of the medical research company’s stock valued at $7,498,000 after buying an additional 4,856 shares during the period. Tower Research Capital LLC TRC raised its holdings in Charles River Laboratories International by 8.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,604 shares of the medical research company’s stock valued at $706,000 after buying an additional 292 shares during the period. Bank of Nova Scotia raised its holdings in Charles River Laboratories International by 24.2% in the third quarter. Bank of Nova Scotia now owns 2,634 shares of the medical research company’s stock valued at $516,000 after buying an additional 513 shares during the period. Gotham Asset Management LLC raised its holdings in Charles River Laboratories International by 13.0% in the third quarter. Gotham Asset Management LLC now owns 16,077 shares of the medical research company’s stock valued at $3,151,000 after buying an additional 1,844 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its holdings in Charles River Laboratories International by 222.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 12,004 shares of the medical research company’s stock valued at $2,353,000 after buying an additional 8,285 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).